{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T18:53:46Z","timestamp":1773687226510,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.semarthrit.2016.09.007","type":"journal-article","created":{"date-parts":[[2016,9,20]],"date-time":"2016-09-20T14:30:13Z","timestamp":1474381813000},"page":"754-758","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout"],"prefix":"10.1016","volume":"46","author":[{"given":"Adey A.","family":"Berhanu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Krasnokutsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert T.","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Pillinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2016.09.007_bib1","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007\u20132008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.09.007_bib2","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/rheumatology\/kep047","article-title":"Perceptions of disease and health-related quality of life among patients with gout","volume":"48","author":"Lee","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2016.09.007_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11926-014-0492-x","article-title":"The gouty tophus: a review","volume":"17","author":"Chhana","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.semarthrit.2016.09.007_bib4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.semarthrit.2016.09.007_bib5","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2016.09.007_bib6","first-page":"CD008335","article-title":"Pegloticase for chronic gout","volume":"3","author":"Anderson","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semarthrit.2016.09.007_bib7","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1186\/ar4318","article-title":"Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy","volume":"15","author":"Baraf","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2016.09.007_bib8","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"Suppl. 10","key":"10.1016\/j.semarthrit.2016.09.007_bib9","article-title":"Serum uric acid as a biomarker for mitigation of infusion reactions in patients treated wiht pegloticase for refractory chronic gout","volume":"66","author":"Baraf","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.09.007_bib10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","article-title":"The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases","volume":"53","author":"Jani","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2016.09.007_bib11","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar4500","article-title":"Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2016.09.007_bib12","first-page":"200","article-title":"Immunogenicity\u2014implications for rheumatoid arthritis treatment","volume":"71","author":"Solomon","year":"2013","journal-title":"Bull Hosp Jt Dis"},{"key":"10.1016\/j.semarthrit.2016.09.007_bib13","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2032s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2016.09.007_bib14","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.cgh.2012.10.020","article-title":"Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease","volume":"11","author":"Ben-Horin","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl. 1","key":"10.1016\/j.semarthrit.2016.09.007_bib15","first-page":"DOP066","article-title":"Disappearance of anti-drug antibodies to infliximab and adalimumab after addition of an immunomodulator in patients with inflammatory bowel disease","volume":"10","author":"Strik","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.semarthrit.2016.09.007_bib16","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1172\/JCI105643","article-title":"The effects of azathioprine (imuran) on purine synthesis in clinical disorders of purine metabolism","volume":"46","author":"Kelley","year":"1967","journal-title":"J Clin Invest"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216302888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216302888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T08:33:11Z","timestamp":1536395591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017216302888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0049017216302888"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2016.09.007","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2016.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}